Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies. Issue 3 (28th July 2022)

• Record Type: Journal Article
• Authors: Siebenaler, Ronald F; Chugh, Seema; Waninger, Jessica J; Dommeti, Vijaya L; Kenum, Carson; Mody, Malay; Gautam, Anudeeta; Patel, Nidhi; Chu, Alec; Bawa, Pushpinder; Hon, Jennifer; Smith, Richard D; Carlson, Heather; Cao, Xuhong; Tesmer, John J G; Shankar, Sunita; Chinnaiyan, Arul M
• Editors: Furmanski, Philip
• Is Part Of: PNAS nexus. Volume 1:Issue 3(2022)
• Publication Date: 2022-07-28
• Subjects: HRAS -- NRAS -- EGFR -- Argonaute 2 -- senescence; Science -- Periodicals; 505
• DOI: 10.1093/pnasnexus/pgac084
• Languages: English
• ISSNs: 2752-6542

Abstract

Abstract: Activating mutations in RAS GTPases drive nearly 30% of all human cancers. Our prior work described an essential role for Argonaute 2 (AGO2), of the RNA-induced silencing complex, in mutant KRAS -driven cancers. Here, we identified a novel endogenous interaction between AGO2 and RAS in both wild-type (WT) and mutant HRAS / NRAS cells. This interaction was regulated through EGFR-mediated phosphorylation of Y393-AGO2, and utilizing molecular dynamic simulation, we identified a conformational change in pY393-AGO2 protein structure leading to disruption of the RAS binding site. Knockdown of AGO2 led to a profound decrease in proliferation of mutant HRAS / NRAS -driven cell lines but not WT RAS cells. These cells demonstrated oncogene-induced senescence (OIS) as evidenced by β-galactosidase staining and induction of multiple downstream senescence effectors. Mechanistically, we discovered that the senescent phenotype was mediated via induction of reactive oxygen species. Intriguingly, we further identified that loss of AGO2 promoted a novel feed forward pathway leading to inhibition of the PTP1B phosphatase and activation of EGFR–MAPK signaling, consequently resulting in OIS. Taken together, our study demonstrates that the EGFR–AGO2–RAS signaling axis is essential for maintaining mutant HRAS and NRAS -driven malignancies.